{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:49:55Z","timestamp":1767649795903,"version":"3.38.0"},"reference-count":7,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2018,3,25]],"date-time":"2018-03-25T00:00:00Z","timestamp":1521936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>Aim:<\/jats:title><jats:p> To evaluate early prostate cancer cryoablation functional and oncological results in comparison with results of extraperitoneoscopic radical prostatectomy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods:<\/jats:title><jats:p> We analyzed early results of surgical treatment of 285 patients with prostate cancer: 42 of them had undergone total cryoablation (Group 1) while the rest of them had been treated by radical laparo- and extraperitoneoscopic prostatectomy. For comparative assessment of prostate cryoablation results, 42 patients from Group 2 randomized in accordance with their age, stage of disease, Gleason, prostate-specific antigen, and prostate volume were selected. In compliance with the results of pre-surgical examination, all the patients had low oncological risk and were not concerned in sexual function. Volume of prostate was from 22 to 65\u2009cm<jats:sup>3<\/jats:sup>, prostate-specific antigen level was from 4.1 to 10\u2009ng\/mL, and level of neoplastic process differentiation using Gleason grading system was from 6 to 7a (3\u2009+\u20094) scores. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> Patients after prostate cryoablation in early post-surgical period felt lower intensity of postoperative pain compared with those who had undergone prostatectomy. Follow-up period up to 12\u2009months manifested significant true reduction of prostate-specific antigen level in both groups of patients. Frequency of stress-induced enuresis in Group 1 was not observed. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> Radical prostatectomy is still the traditional treatment of choice in the case of localized prostate cancer. But we can draw the conclusion that cryoablation is an effective low-invasive method for treatment of low oncological risk patients, which gives the opportunity both to achieve good oncological results and to preserve high life quality. <\/jats:p><\/jats:sec>","DOI":"10.1177\/0391560317749425","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T17:56:55Z","timestamp":1527875815000},"page":"68-72","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative results of cryoablation and laparoscopic radical prostatectomy in the treatment of localized prostate cancer"],"prefix":"10.1177","volume":"85","author":[{"given":"Denis Vladimirovich","family":"Chinenov","sequence":"first","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid Mikhailovich","family":"Rapoport","sequence":"additional","affiliation":[{"name":"Clinic of Urology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeniy Valerievich","family":"Shpot","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry Victorovich","family":"Enikeev","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaroslav Nikolaevich","family":"Chernov","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark Sergeevich","family":"Taratkin","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry Olegovich","family":"Korolev","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,3,25]]},"reference":[{"volume-title":"Guidelines on prostate cancer","year":"2015","author":"Mottet N","key":"bibr1-0391560317749425"},{"key":"bibr2-0391560317749425","unstructured":"World Health Organization: International Agency for Research on Cancer. Prostate cancer: estimated incidence, mortality & prevalence, 2012, http:\/\/eco.iarc.fr\/eucan\/CancerOne.aspx?Cancer=29&Gender=1"},{"key":"bibr3-0391560317749425","unstructured":"Malignant neoplasm morbidity in the Russian Federation regions FGU CNIIOIZ Ministry of social development of RF. FGBU Central NII for public health organization and informatization of Ministry of public health of RF, 2007, http:\/\/mednet.ru\/images\/stories\/files\/statistika\/Zabolevaemost_zlokachestvennymi_novoobrazovaniyami_v_subektah_RF.pdf"},{"key":"bibr4-0391560317749425","unstructured":"Socially significant diseases of Russian population in 2015. FGBU Central Scientific and Research Institute for Organization and Informatization of Public Health attached to the Ministry of Public Health of Russia. FGBU Central NII for organization and informatization of public health Ministry of public health of RF, 2016, http:\/\/mednet.ru\/images\/stories\/files\/statistika\/socialno-znachimie_zabolevaniya\/ssz2015.pdf"},{"key":"bibr5-0391560317749425","unstructured":"World Health Organization. Mortality indicator database: standardized death rates per 100000, malignant neoplasm of prostate (European mortality database), 2016, http:\/\/data.euro.who.int\/hfamdb\/"},{"key":"bibr6-0391560317749425","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-015-3864-6"},{"issue":"10","key":"bibr7-0391560317749425","doi-asserted-by":"crossref","first-page":"e006382","DOI":"10.1136\/bmjopen-2014-006382","volume":"4","author":"Van De","year":"2014","journal-title":"BMJ Open"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0391560317749425","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0391560317749425","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0391560317749425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:49:44Z","timestamp":1740768584000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0391560317749425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,25]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1177\/0391560317749425"],"URL":"https:\/\/doi.org\/10.1177\/0391560317749425","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"type":"print","value":"0391-5603"},{"type":"electronic","value":"1724-6075"}],"subject":[],"published":{"date-parts":[[2018,3,25]]}}}